NEO Neogenomics (NEO) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Services-testing laboratories · CIK 0001077183
Congress · 1Form 144 · 2
Insider buyers, 180 days
0
Funds added, last quarter
157
13F, latest reported quarter
Conversions, 180 days
14
Codes C/M, not in net · $0 priced
What the filings say about NEO
Insiders, 180 days
-$440.2K net sold
2 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-08-07
Planned sales (Form 144), 90 days
$4.0M
2 notices
Neogenomics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, NEOGENOMICS INC insiders sold a net $440.2K of stock across 29 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 388.1% of the 5,153 shares held after it.
- No other insider sold within 30 days.
- 157 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Aunan Greg D sold about $321.4K of NEO on Aug 4, 2026, the largest insider sale at the company since 2021; 157 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Jun 9, 2026.
- The trade is 6.2% of the 86,115 shares held after it.
- No other insider sold within 30 days.
- 157 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director TETRAULT LYNN A. sold about $58.9K of NEO on Jun 15, 2026; 157 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on May 9, 2025.
- The trade is 5.8% of the 91,422 shares held after it.
- No other insider sold within 30 days.
- 157 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director TETRAULT LYNN A. sold about $59.9K of NEO on Jun 9, 2026; 157 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 12, 2025.
- The trade is 18.2% of the 121,631 shares held after it.
- No other insider sold within 30 days.
- 157 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Pres & Chief Operating Officer Stone Warren sold about $276.6K of NEO on Jan 20, 2026, the largest insider sale at the company since 2021; 157 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Oct 16, 2025.
- The trade is 67.3% of the 31,083 shares held after it.
- No other insider sold within 30 days.
- 157 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, GC & Business Development Olivo Alicia C sold about $251.0K of NEO on Nov 25, 2025, the largest insider sale at the company since 2021; 157 funds added in the latest 13F quarter.29 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$440.2K over 180 days
-$321.4K over 90 days
below 55% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
157 funds bought in last quarter
more than 84% of Pharma & Biotech
Revenue
+10.1% year over year
more than 59% of Pharma & Biotech
Margin
-14.9% net margin
more than 60% of Pharma & Biotech
Buybacks
$25.0M repurchased, FY to 2026-06-30
below 59% of Pharma & Biotech
Short interest
12.1% of the float short (float per yahoo 2026-10-26) · 5.7 days to cover · settled 2026-09-30
more than 74% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch NEO
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+59.7%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns NEO: institutional holders (13F)
13F holdings, latest reported quarter
20,868,362 sh
$304.5M
12,279,523 sh
$179.2M
10,113,261 sh
$147.6M
8,574,210 sh
$125.1M
8,061,362 sh
$117.6M
Congress trades in NEO
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-08-07 · disclosed 34 days later
$1,001 - $15,000
Bought 2025-05-07 · disclosed 30 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
NEO planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
GREG AUNAN
Filed 2026-08-04
$321.5K
JEFFREY SHERMAN
Filed 2026-07-30
$3.7M
NEO mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Baird Equity Opportunity Fund
$4.1M position · as of 2026-06-30
5.3%
First Trust NYSE Arca Biotechnology Index Fund
$144.0M position · as of 2026-06-30
5.1%
State Street(R) SPDR(R) S&P(R) Health Care Services ETF
$2.9M position · as of 2026-06-30
2.1%
Hartford Schroders US Small Cap Opportunities Fund
$2.7M position · as of 2026-07-31
1.5%
AMG GW&K Small Cap Value Fund
$3.6M position · as of 2026-06-30
1.5%
Small Cap Equity Portfolio
$15.7M position · as of 2026-07-31
1.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Christopher Smith
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$11.3M
$10.3M
$2.8M
-44%
+18%
2023
$11.7M
$16.4M
$3.4M
-45%
+19%
2020
$4.1M
$14.7M
$972.6K
+84%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $440.2K sold by insiders over 180 days, 157 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $4.0M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
NEO financials
Revenue growth
+10.1%
XBRL, annual
Net margin
-14.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$766.3M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM NEO
| FY Dec 2025 | $727.3M |
| FY Dec 2024 | $660.6M |
| FY Dec 2023 | $591.6M |
| FY Dec 2022 | $509.7M |
| FY Dec 2021 | $484.3M |
| Jun 2026 | $201.7M |
| Mar 2026 | $186.7M |
| Dec 2025 | $190.2M |
| Sep 2025 | $187.8M |
| Jun 2025 | $181.3M |
| Mar 2025 | $168.0M |
| Dec 2024 | $172.0M |
| Sep 2024 | $167.8M |
At each fiscal year end
Single quarter
Net margin, TTM
-6.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM NEO
| FY Dec 2025 | -14.8% |
| FY Dec 2024 | -12.0% |
| FY Dec 2023 | -14.9% |
| FY Dec 2022 | -28.3% |
| FY Dec 2021 | -1.7% |
| Jun 2026 | +1.1% |
| Mar 2026 | -9.2% |
| Dec 2025 | -5.2% |
| Sep 2025 | -14.4% |
| Jun 2025 | -24.9% |
| Mar 2025 | -15.4% |
| Dec 2024 | -9.1% |
| Sep 2024 | -10.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$7.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM NEO
| FY Dec 2025 | -$21.8M |
| FY Dec 2024 | -$34.0M |
| FY Dec 2023 | -$30.7M |
| FY Dec 2022 | -$96.9M |
| FY Dec 2021 | -$90.9M |
| Jun 2026 | $11.7M |
| Mar 2026 | -$13.1M |
| Dec 2025 | -$6.5M |
| Sep 2025 | $570.0K |
| Jun 2025 | $14.0M |
| Mar 2025 | -$29.8M |
| Dec 2024 | -$1.8M |
| Sep 2024 | -$1.6M |
At each fiscal year end
Single quarter
Debt to equity
0.48x
long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end); equity 2026-06-30
Debt to equity NEO
| FY Dec 2025 | 0.41x |
| FY Dec 2024 | 0.60x |
| FY Dec 2023 | 0.57x |
| FY Dec 2022 | 0.54x |
| FY Dec 2021 | 0.48x |
| Jun 2026 | 0.48x |
| Mar 2026 | 0.41x |
| Dec 2025 | 0.41x |
| Sep 2025 | 0.65x |
| Jun 2025 | 0.63x |
| Mar 2025 | 0.61x |
| Dec 2024 | 0.60x |
| Sep 2024 | 0.37x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.06x
TTM operating cash flow over long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end)
Cash flow to debt NEO
| FY Dec 2025 | 0.02x |
| FY Dec 2024 | 0.01x |
| FY Dec 2023 | -0.00x |
| FY Dec 2022 | -0.12x |
| FY Dec 2021 | -0.05x |
| Jun 2026 | 0.06x |
| Mar 2026 | 0.07x |
| Dec 2025 | 0.02x |
| Sep 2025 | 0.03x |
| Jun 2025 | 0.03x |
| Mar 2025 | 0.01x |
| Dec 2024 | 0.01x |
| Sep 2024 | 0.04x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-6.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity NEO
| FY Dec 2025 | -12.4% |
| FY Dec 2024 | -8.6% |
| FY Dec 2023 | -9.1% |
| FY Dec 2022 | -13.7% |
| FY Dec 2021 | -0.9% |
| Jun 2026 | -6.3% |
| Mar 2026 | -11.6% |
| Dec 2025 | -12.4% |
| Sep 2025 | -13.0% |
| Jun 2025 | -11.8% |
| Mar 2025 | -8.6% |
| Dec 2024 | -8.6% |
| Sep 2024 | -8.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-3.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets NEO
| FY Dec 2025 | -7.2% |
| FY Dec 2024 | -4.8% |
| FY Dec 2023 | -5.1% |
| FY Dec 2022 | -8.0% |
| FY Dec 2021 | -0.6% |
| Jun 2026 | -3.8% |
| Mar 2026 | -6.7% |
| Dec 2025 | -7.2% |
| Sep 2025 | -7.5% |
| Jun 2025 | -6.9% |
| Mar 2025 | -4.8% |
| Dec 2024 | -4.8% |
| Sep 2024 | -4.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital NEO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-5.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed NEO
| FY Dec 2025 | -8.9% |
| FY Dec 2024 | -6.3% |
| FY Dec 2023 | -6.7% |
| FY Dec 2022 | -9.2% |
| FY Dec 2021 | -8.8% |
| Jun 2026 | -5.4% |
| Mar 2026 | -8.2% |
| Dec 2025 | -8.9% |
| Sep 2025 | -9.2% |
| Jun 2025 | -8.7% |
| Mar 2025 | -6.2% |
| Dec 2024 | -6.3% |
| Sep 2024 | -6.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing NEO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$2.4B
market value at close 2026-10-26 on 2026-07-24 shares, plus long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end), minus cash 2026-06-30
Enterprise value NEO
| FY Dec 2025 | $1.7B |
| FY Dec 2024 | $2.3B |
| FY Dec 2023 | $2.3B |
| FY Dec 2022 | $1.4B |
| FY Dec 2021 | $4.4B |
| Jun 2026 | $2.1B |
| Mar 2026 | $1.2B |
| Dec 2025 | $1.7B |
| Sep 2025 | $1.4B |
| Jun 2025 | $1.3B |
| Mar 2025 | $1.4B |
| Dec 2024 | $2.3B |
| Sep 2024 | $1.9B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-0.3%
TTM free cash flow over market value at close 2026-10-26
FCF yield NEO
| FY Dec 2025 | -1.4% |
| FY Dec 2024 | -1.6% |
| FY Dec 2023 | -1.5% |
| FY Dec 2022 | -8.3% |
| FY Dec 2021 | -2.2% |
| Jun 2026 | -0.4% |
| Mar 2026 | -0.5% |
| Dec 2025 | -1.4% |
| Sep 2025 | -1.7% |
| Jun 2025 | -2.0% |
| Mar 2025 | -2.7% |
| Dec 2024 | -1.6% |
| Sep 2024 | -1.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing NEO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $727.3M | $660.6M | $591.6M | $509.7M |
| Gross profit | $314.3M | $290.1M | $244.6M | $187.9M |
| Operating income | -$115.9M | -$92.1M | -$107.7M | -$157.6M |
| Net income | -$108.0M | -$79.0M | -$88.0M | -$144.0M |
| Operating cash flow | $5.2M | $7.0M | -$2.0M | -$66.0M |
| Cash | $159.6M | $367.0M | $342.5M | $263.2M |
| Long-term debt | $341.9M | $340.3M | $538.2M | $535.3M |
SEC XBRL, fiscal years, as known on 2026-10-28
NEO Stock Sonar score 6/7 axes
Find similar shapesCompareNEO ranks highest on profitability (80th percentile) and growth (72nd), and lowest on insider conviction (21st), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
NEO filings, in plain words
Are Neogenomics insiders buying or selling NEO?
In the 180 days to 2026-10-28, Neogenomics insiders were net sellers, a net $440.2K across purchases and sales reported on Form 4, by 2 sellers.
Have members of Congress traded NEO?
Yes. In the year to 2026-10-28, 1 House member disclosed buying NEO and 0 House members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-08-07.
Are there planned insider sales of NEO?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $4.0M of stock; the latest, by GREG AUNAN, was filed 2026-08-04.
Read the full summary
In the 180 days to 2026-10-28, Neogenomics insiders were net sellers of NEO, a net $440.2K across purchases and sales reported on Form 4 by 2 sellers. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-28, 1 member of Congress disclosed buying NEO and 0 members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-08-07. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $4.0M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
